Triple-Negative Breast Cancer Clinical Trial
Official title:
Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer
NCT number | NCT02985658 |
Other study ID # | 9763 |
Secondary ID | RG1716061NCI-202 |
Status | No longer available |
Phase | |
First received | |
Last updated |
Verified date | July 2021 |
Source | University of Washington |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Expanded Access |
This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are currently receiving the investigational product in association with clinical trial participation. Additionally, the protocol will enroll up to 7 new patients with metastatic BRCA associated or triple negative breast cancer to allow for additional access to veliparib monotherapy, or at the investigator's discretion, veliparib in combination with cisplatin and/or vinorelbine.
Status | No longer available |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | Female |
Age group | 18 Years and older |
Eligibility | 1. Inclusion Criteria Roll-over patients: This protocol allows for the inclusion of 3 patients actively participating in protocol 7161 who are expected to continue to benefit from uninterrupted dosing of veliparib monotherapy. For newly enrolled patients the following criteria should be satisfied within 28 days of Day 1 of protocol treatment. Results from routine clinical evaluations within 28 days prior to enrollment may be used to determine eligibility: - Locally recurrent and not amenable to surgical therapy, and/or metastatic breast cancer - Confirmed HER2-, BRCA1 or BRCA2 mutation-associated breast cancer or sporadic triple negative breast cancer. - No opportunity to receive veliparib under a current clinical trial. - Patients may have had any number of prior lines of chemotherapy, endocrine therapy, immunologic, or biologic regimens for metastatic breast cancer. - Patients receiving bisphosphonates, denosumab or LHRH-agonists are eligible. - 18 years and older. - Performance status > 60% on the Karnofsky scale (ECOG < 2). - Adequate hematologic, renal and hepatic function as follows: - Bone Marrow: Absolute neutrophil count (ANC) > 1,500/mm3 (1.5 × 109/L); Platelets > 100,000/mm3 (100 × 109/L); Hemoglobin > 9.0 g/dL - Serum creatinine < 1.5 × upper normal limit of institution's normal range OR creatinine clearance > 50 mL/min/1.73m2 for patients with creatinine levels above institutional normal; - Hepatic function: AST and/or ALT < 2.5 × the upper normal limit of institution's normal range. o For patients with liver metastases, AST and/or ALT < 5 × the upper normal limit of institution's normal range; - Bilirubin < 1.5 × the upper normal limit of institution's normal range; o Patients with Gilbert's Syndrome may have a bilirubin > 1.5 × the upper normal limit of institution's normal range. - Women of childbearing potential must agree to use adequate contraception (one of the following listed below) prior to protocol entry, for the duration of protocol participation and for 90 days following completion of therapy. Women of childbearing potential must have a negative serum pregnancy test within 21 days prior to initiation of treatment and/or be confirmed as having postmenopausal status. Criteria for determining menopause include any of the following: prior bilateral oopherectomy; age > 60 years; age < 60 years and amenorrheic for at least 12 months in the absence of chemotherapy, endocrine therapy, or ovarian suppression and FSH and estradiol in the postmenopausal range. - Total abstinence from sexual intercourse (minimum one complete menstrual cycle); - Vasectomized partner of female patients; - Hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration; - Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream); - IUD (Intra-Uterine Device). - Additionally, male patients (including those who are vasectomized) whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the treatment plan and for 90 days following completions of therapy. - Radiation therapy must have been completed at least 2 weeks prior to the enrollment date. - Patients with known brain metastases must have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 14 days of stable neurologic function prior to the first dose of study drug. - Ability to understand and the willingness to sign a written informed consent document. 2. Exclusion Criteria - Prior treatment with PARP inhibitor (excluding iniparib). Patients participating in protocol 7161 (NCI-2010-00356) are eligible. - Clinically significant and uncontrolled major medical condition(s) including but not limited to: - Active uncontrolled infection; - Symptomatic congestive heart failure; - Unstable angina pectoris or cardiac arrhythmia; - Psychiatric illness/social situation that would limit compliance with protocol requirements; - Any medical condition, which in the opinion of the investigator, places the patient at an unacceptably high risk for toxicities; - Myelodysplastic syndrome; - History of seizures within last 12 months or known neurological disorder pre-disposing to seizures - Patient is pregnant or lactating. |
Country | Name | City | State |
---|---|---|---|
United States | Seattle Cancer Care Allliance | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Washington | AbbVie |
United States,
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005 Apr 14;434(7035):913-7. Erratum in: Nature. 2007 May 17;447(7142):346. — View Citation
Chiarugi A. Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol Sci. 2002 Mar;23(3):122-9. Review. — View Citation
Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z, Newell DR. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res. 2004 Feb 1;10(3):881-9. — View Citation
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005 Apr 14;434(7035):917-21. — View Citation
Hirai K, Ueda K, Hayaishi O. Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. Cancer Res. 1983 Jul;43(7):3441-6. — View Citation
Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. J Clin Invest. 2004 Jan;113(2):160-8. Review. — View Citation
Virág L, Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002 Sep;54(3):375-429. Review. — View Citation
Wielckens K, Garbrecht M, Kittler M, Hilz H. ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells. Eur J Biochem. 1980 Feb;104(1):279-87. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03639948 -
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT02427581 -
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
|
Phase 1 | |
Completed |
NCT04584112 -
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Terminated |
NCT01918306 -
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04914390 -
A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer
|
Phase 2 | |
Completed |
NCT03154749 -
DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
|
Phase 2 | |
Completed |
NCT04504916 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
|
Phase 2 | |
Completed |
NCT03345485 -
Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04582955 -
Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy
|
N/A | |
Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01695057 -
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
|
N/A | |
Terminated |
NCT01234532 -
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT03805399 -
FUSCC Refractory TNBC Umbrella (FUTURE)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04129996 -
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
|
Phase 2 | |
Terminated |
NCT03621982 -
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05336721 -
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
|
Phase 2 | |
Terminated |
NCT03674827 -
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
|
Phase 1 | |
Completed |
NCT04177108 -
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
|
Phase 3 |